Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
Rhea-AI Summary
Mersana Therapeutics (NASDAQ: MRSN) announced it will report business updates and third quarter 2025 financial results for the period ended September 30, 2025 on Friday, November 14, 2025.
The company will host a conference call and live webcast on November 14, 2025 at 8:00 a.m. Eastern Time. Domestic dial-in is 833-255-2826, international dial-in is 412-317-0689. A replay of the webcast will be available on the Investors & Media section of www.mersana.com for approximately 90 days following the call.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MRSN gained 2.38%, reflecting a moderate positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $44M at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that have generated a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Mersana@argotpartners.com
FAQ
When will Mersana Therapeutics (MRSN) report Q3 2025 results?
What time is the Mersana (MRSN) conference call for Q3 2025?
How can investors access the Mersana (MRSN) Q3 2025 webcast?
What are the dial-in numbers for Mersana (MRSN) Q3 2025 earnings call?
How long will the Mersana (MRSN) webcast replay be available?
Will Mersana (MRSN) provide business updates during the Q3 2025 call?
